BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-biontech-2026-oncology-late-stage-readout-window@catalyst-calendar.local
DTSTAMP:20260720T200555Z
DTSTART:20260701T130000Z
DTEND:20260701T133000Z
SUMMARY:BioNTech 2026后期肿瘤管线读出与BLA提交窗口更新
DESCRIPTION:BioNTech在2026年战略更新和一季报中披露，2026年将有多个后期肿瘤里程碑，并与DualityBio计划在2026年就trastuzumab pamirtecan提交BLA（取决于FDA反馈）。事件影响ADC、免疫调节和中国授权资产在全球后期开发中的估值锚。\\nImpact score: 65\\nExpected: 市场关注BLA提交是否落地、FDA反馈是否清晰，以及BioNTech首批后期肿瘤资产能否支撑其从疫苗公司向多产品肿瘤公司的估值转换。\\nAffected: BNTX(subject\, mixed\, score 78)\; 09606.HK(licensor\, mixed\, score 70)\; BMY(licensee\, mixed\, score 60)\; 688506.SH(peer\, mixed\, score 58)\; IBB(etf\, mixed\, score 50)\; ROG.SW(peer\, mixed\, score 48)\\nSources: BioNTech 2026 strategic update: https://www.biontech.com/int/en/home/mediaroom/news/press-releases/2026/01/biontech-provides-strategic-business-update-and-outlines-2026.html\\nBioNTech Q1 2026 results: https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-quarter-2026-financial-results-and\\nBioNTech DualityBio ADC Phase 3/BLA release: https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybios-antibody-drug-conjugate-trastuzumab\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-biontech-2026-oncology-late-stage-readout-window
CATEGORIES:guidance\,US\,BioNTech\,ADC\,bispecific\,mRNA cancer vaccine\,clinical readout\,DualityBio\,BLA\,oncology
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: BioNTech 2026后期肿瘤管线读出与BLA提交窗口更新
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: BioNTech 2026后期肿瘤管线读出与BLA提交窗口更新
END:VALARM
END:VEVENT
END:VCALENDAR